Luca Faloppi
Overview
Explore the profile of Luca Faloppi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Filippi R, Brandi G, Casadei-Gardini A, Leone F, Silvestris N, Satolli M, et al.
Cancer Invest
. 2024 Nov;
43(1):59-69.
PMID: 39601419
Despite a biologically established causative role of viral hepatitis (VH), i.e. HBV and HCV infections, on intrahepatic cholangiocarcinoma (ICC), only few large Western cohorts exploring the association between VH and...
2.
Carconi C, Bosi C, Scartozzi M, Cergnul M, Cinausero M, Faloppi L, et al.
Pancreatology
. 2024 Sep;
24(7):1066-1072.
PMID: 39277480
Backgorund: Pancreatic adenocarcinoma remains a malignancy with a grim prognosis and scarce personalized treatment options. Pathogenic variants of DNA damage repair (DDR) genes are emerging as molecular targets, as they...
3.
Reni M, Giordano G, Audisio M, Orsi G, Macchini M, Gobba S, et al.
Dig Liver Dis
. 2024 Jul;
57(1):104-110.
PMID: 39003164
Introduction: Cisplatin, nab-paclitaxel, capecitabine, and gemcitabine (PAXG) regimen activity was assessed in a single institution phase II trial (PACT-19) on pancreatic ductal adenocarcinoma (PDAC). The PACT-31 study explored the external...
4.
Casadei-Gardini A, Leone F, Brandi G, Scartozzi M, Silvestris N, Santini D, et al.
Front Oncol
. 2023 Apr;
13:1128930.
PMID: 37091141
Cholangiocarcinoma is a rare group of tumors that involve the hepatic biliary tree. Prognosis for patients with cholangiocarcinoma remains dismal. Herein, we present survival trends over a long time period...
5.
Loi E, Zavattari C, Tommasi A, Moi L, Canale M, Po A, et al.
Br J Cancer
. 2022 Feb;
126(12):1783-1794.
PMID: 35177798
Background: Biliary tract cancers (BTC) are rare but highly aggressive tumours with poor prognosis, usually detected at advanced stages. Herein, we aimed at identifying BTC-specific DNA methylation alterations. Methods: Study...
6.
Rimini M, Casadei-Gardini A, Brandi G, Leone F, Fornaro L, Pella N, et al.
J Chemother
. 2022 Feb;
34(8):543-549.
PMID: 35156913
Biliary tract cancer's (BTC) treatment main stone for advanced stages is constituted by chemotherapy. Surgical centralization and physicians' confidence in the use of new technologies and molecular analysis turned out...
7.
Santoni M, Rizzo A, Mollica V, Matrana M, Rosellini M, Faloppi L, et al.
Crit Rev Oncol Hematol
. 2022 Jan;
170:103596.
PMID: 35031442
The primary endpoint of MOUSEION-01 was to assess overall survival (OS) in male and female patients receiving immune checkpoint inhibitors versus control treatments, calculating the pooled OS Hazard Ratio (HR)...
8.
Rizzo A, Santoni M, Mollica V, Logullo F, Rosellini M, Marchetti A, et al.
Expert Opin Drug Metab Toxicol
. 2022 Jan;
17(12):1455-1466.
PMID: 35029519
Introduction: Treatment-related neurotoxicity is a common side effect in cancer patients. However, few data are available regarding the risk of several neurotoxicities in patients treated with immune checkpoint inhibitors. Areas...
9.
Ballatore Z, Merloni F, Ranallo N, Bastianelli L, Vitarelli F, Cantini L, et al.
Psychooncology
. 2021 Jul;
31(1):39-45.
PMID: 34315188
Objective: The coronavirus disease 2019 (COVID-19) outbreak has been declared a global pandemic of unprecedented proportions. Italy is a country which has been heavily affected. Cancer patients are at a...
10.
Filippi R, Montagnani F, Lombardi P, Fornaro L, Aprile G, Casadei-Gardini A, et al.
Acta Oncol
. 2021 Jul;
60(10):1317-1324.
PMID: 34282710
Background: Standard treatment of advanced biliary tract cancer (aBTC) is represented by first-line chemotherapy (CT1). However, some patients do not gain any benefit from CT1, contributing to the overall dismal...